Thymic langerhans cell histiocytosis in children: A case report

Marie Poncelet1, Camille Chabert2, Jean Pierre Pracros2, Perrine Marec Berard1

1Pediatric Institute of Hematology and Oncology, Institut d’Hématologie et d’Oncologie Pédiatrique (IHOP), Lyon, France
2Pediatric Unit of Radiology, Hôpital Femme Mère Enfant (HFME), Lyon, France
Email: *poncelet.marie@yahoo.fr

Received 14 August 2012; revised 17 September 2012; accepted 5 October 2012

ABSTRACT

Langerhans cell histiocytosis has long been described as a rare systemic disorder involving the proliferation of Langerhans cells with formation of granuloma. The disease may be localised or diffuse. Typical forms of the disease involving the bone, the skin or the pituitary gland have been well described whereas others, such as thymic histiocytosis, are still poorly understood. Here, we report a case of isolated Langerhans cell histiocytosis of the thymus in an infant with non-specific symptoms. We provide a description of the disease and discuss patient management.

Keywords: Langerhans Cell Histiocytosis; Children; Thymus

1. INTRODUCTION

Langerhans Cell Histiocytosis (LCH) is a complex systemic disorder characterized by an abnormal proliferation of Langerhans cells, generally organized in granulomas. The estimated prevalence is between 1 and 2 per 100,000 population [1]. The organs most frequently involved are the bone, the skin, the pituitary gland, the lung and, less commonly, the hematopoietic system, the liver and the central nervous system [2]. Thymus involvement is rare. LCH typically occurs in children as part of a multifocal, multisystem process [3,4]. Only few reports of isolated tumours involving the thymus have been published in adults, either in association with coexistent myasthenia gravis [5,6], low-grade leiomyosarcoma [7] or multilocular thymic cyst [8]. In the literature we found only a single case of a child who presented an isolated thymic LCH, mimicking lymphoma [9].

2. OBSERVATION

The patient was a 9-month-old child admitted to hospital for investigation of a 2-month history of recurrent fever, especially at night, associated with intermittent cough. Blood tests showed an elevated leukocyte count (20 G/L) with microcytic anaemia (haemoglobin 85 g/L), 664 G/L platelets and 114 mg/L C-reactive protein. Chest X-ray revealed an enlargement of the thymus (Figure 1), and many diffuse, multicentric micro-calcifications were detected by ultrasound (Figure 2). The patient underwent complementary Computed Tomographic (CT)-scan evaluation (Figure 3) and diagnosis was confirmed by histological examination of transparietal fine-needle aspiration biopsies. Histological sections revealed large cells characterized by grooved, convoluted, off-centred nuclei and abundant eosinophilic cytoplasm, associated with high polynuclear cell levels. The cells were strongly reactive for CD1a and moderately expressed S100 protein. These findings were consistent with the diagnosis of Langerhans cell granuloma or histiocytosis X.

Subsequent staging revealed no other disease site. A combination therapy with vinblastine (Velbe®) and steroids was administered weekly for 6 consecutive weeks, as recommended by current French guidelines. Radiological control after 6 weeks showed complete response to treatment (Figure 4). Maintenance treatment consisted of one course every 3 weeks for 6 months, with control chest X-ray every 2 months. CT-scan examination after the end of treatment confirmed complete remission of the disease (Figure 5).

3. DISCUSSION

Because of its rarity, LCH remains poorly understood. The disease was first described in 1953 by Lichtenstein under the term “histiocytosis X”. This entity encompassed a group of rare syndromes of unknown aetiology such as eosinophilic granuloma, Letterer-Siwe disease or Hand-Schuller-Christian disease [9]. In 1987, because of the presence in the tumour of Langerhans cells—a subgroup of dendritic histiocytes initially described by Paul Langerhans in 1868 [10], the name was changed to “Langerhans cell histiocytosis [11]”.

*Conflict of interest: The authors haven’t any financial relationship with anyone about this research.
#Corresponding author.
The disease pattern, i.e. whether LCH is localized or occurs as part of a multisystem process, is known to be a marker of severity [2]. In patients with high-risk multisystem disease, the most effective treatment strategy involves a combination of chemotherapy and steroids to limit the risk of complications and improve outcome. By extension, this treatment tends to be also applied in patients with lower risk, localized LCH. Reports of LCH within the thymus are less frequent than within the bone, the skin or the endocrine system. Although thymic lesions are commonly reported in the setting of multisystem disease [12], isolated forms are rare. Indeed, in a series of 14 LCH patients with thymic involvement, either at presentation or during the course of the disease, reported by Junewick and Fitzgerald, 7 had multisystem involvement, 1 had unisystem but multifocal involvement and 6 had isolated unifocal disease [12]. Several studies have described thymic LCH as an enlargement of the mediastinum due to increased thymic volume. The thymus is enlarged, with lobulated/nodular contours and heterogeneous ultrasound pattern, and possibly contains liquid cysts and/or calcifications [12,13].

As demonstrated here and in other published series (Patient with superior vena cava obstruction at initial diagnosis, for instance [14]), the presentation of the disease is highly variable, which makes diagnosis extremely challenging. In our patient, an history of recurrent childhood diseases led to the radiological examination of the chest which revealed the tumour. Clinical and radiological correlation is essential for diagnosis. Because of these diagnostic difficulties, it is hypothesized that the incidence of LCH may be underestimated, as for instance in very young children with typical thymic enlargement associated or not with non-specific episodes of fever and bronchial or pulmonary infection. The incidental discovery of a thymic LCH in young adult patients with myasthenia gravis is also in favour of this hypothesis [5,6]. Based on these observations, the actual contribution of chemotherapy to the treatment of patients with localized LCH may appear questionable. These patients are likely to have
a good response to treatment [13,14]; however, one may wonder whether they actually derive a benefit from chemotherapy or whether spontaneous regression can be expected [15].

4. CONCLUSION

LCH with thymic involvement is a rare but well described disease. Typically, patients with unifocal tumours have a good prognosis and respond well to chemotherapy, although one may question the appropriateness of treating these patients who may well recover spontaneously. The incidence of LCH is probably underestimated because diagnosis is hampered by the lack of specific clinical presentation and poor knowledge of radiological manifestations of the disease.

REFERENCES


